德国CRISP登记研究:非小细胞肺癌预后因素分析
基于德国CRISP前瞻性登记研究中2082例野生型非小细胞肺癌患者,验证UICC-8分期M描述符对总生存和无进展生存的预后价值,并发现转移器官系统数量和肝转移是独立不良预后因素,据此可合并为高低风险两组。
要点
- M1c患者中位OS/PFS为10.9/5.4个月,显著短于M1a和M1b。
- M1c且≥4个转移器官者OS风险比1.69,PFS风险比1.81。
- M1b肝转移者OS风险比2.70,PFS风险比2.48。
核心结论
- 在野生型NSCLC中,转移器官系统数量增多和肝转移与更差的总生存和无进展生存相关。
研究设计与样本
- 前瞻性德国CRISP登记研究,纳入>150个中心,分析2082例野生型NSCLC患者(629例M1a、249例M1b、1204例M1c)。
- 采用Cox比例风险模型分析治疗前因素的预后影响。
主要发现
- M1a、M1b和M1c患者中位OS分别为16.4、17.8和10.9个月,中位PFS分别为7.2、6.7和5.4个月。
- M1c且≥4个转移器官者较M1c且1-3个器官者OS风险比1.69(p<0.001),PFS风险比1.81(p<0.001)。
- M1b肝转移者较M1b其他器官转移者OS风险比2.70(p=0.006),PFS风险比2.48(p=0.007)。
- 低风险组(M1a、M1b非肝、M1c 1-3器官非肝)与高风险组(M1c肝、M1b肝、M1c≥4器官)中位OS/PFS分别为14.3/6.5个月和7.7/4.1个月。
- 女性、ECOG 0分、T1或N0状态与更长OS相关,年龄无影响。
临床怎么用
- 可利用转移器官系统数量和肝转移对野生型NSCLC患者进行预后分层,辅助治疗决策和姑息照护规划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Understanding prognosis, especially long-term outcome, in advanced nonsmall cell lung cancer (NSCLC) is crucial to inform patients, guide treatment and plan supportive and palliative care. METHODS: Prognostic factors influencing overall survival (OS) and progression-free survival (PFS) in 2082 patients with wild-type (WT)-NSCLC (629 M1a, 249 M1b, 1204 M1c) are reported. Patients were included in the prospective German CRISP registry recruiting in >150 centres. Analysis for pre-therapeutic factors was based on results from Cox proportional hazard models. RESULTS: Current M-descriptors of the Union for International Cancer Control-8 staging system were validated: M1a and M1b patients had significantly longer median time to events compared to M1c (OS/PFS 16.4/7.2 months, 17.8/6.7 months and 10.9/5.4 months, respectively). OS and PFS were influenced by number and location of metastatic organ systems. M1c and four or more metastatic organs involved had shorter OS and PFS than M1c with one to three organs (OS hazard ratio (HR) 1.69, p<0.001; PFS HR 1.81, p<0.001). M1b-liver metastases had shorter OS/PFS than M1b involving other organs (OS HR 2.70, p=0.006; PFS HR 2.48, p=0.007). Based on number of involved organs (orgsys) and liver metastases, two risk groups (low-risk: M1a, M1b-non-liver, M1c-1-3-orgsys-non-liver; high-risk: M1c-liver, M1b-liver, M1c-4+-orgsys) with significantly different prognoses could be amalgamated (median OS/PFS 14.3/6.5 months and 7.7/4.1 months, respectively). Other favourable factors were female gender and Eastern Cooperative Oncology Group stage 0, with age showing no impact. Those with T1- or N0-status were associated with longer OS than T2-4 or N2-3. CONCLUSION: In this large observational dataset, we further defined factors for outcome in WT-NSCLC, including increased number of involved metastatic organ systems and liver metastases, as those with overall poorer prognosis and reduced survival chance.
引用
- Metzenmacher M, Griesinger F, Hummel HD, et al. Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry. Eur Respir J. 2023. PMID: 36180086. doi:10.1183/13993003.01336-2022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。